Thrombophilia and placenta-mediated pregnancy complications: From the bench to bedside to policy

Thrombosis Research

Volumn 123, Issue SUPPL. 2, 2009, Pages

  Rodger, Marc A ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD; FEMALE; HUMAN; PLACENTA DISORDER; PREGNANCY; PREGNANCY COMPLICATION; THROMBOPHILIA;

FEMALE; HUMANS; PLACENTA DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOPHILIA;

EID: 65549086015     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(09)70021-0     Document Type: Article

References (27)

1. Boffa MC, Karmochkine M. Thrombomodulin: An overview and potential implications in vascular disorders. Lupus 1998;7(Suppl 2):S120-5.
2. Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: Does acute endothelial dysfunction provide a link? Lancet 1997;349(9062):1391- 2.
3. Benirschke K, Kaufmann P. Pathology of the Human Placenta, fourth edition. New York: Springer Verlag; 1999.
4. Isermann B, Sood R, Pawlinski R, Zogg M, Kalloway S, Degen JL, et al. The thrombomodulin protein C system is essential for the maintenance of pregnancy. Nat Med 2003;9(3):331-7.
5. Weiler-Guettler H, Christie PD, Beeler DL, Healy AM, Hancock WW, Rayburn H, et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 1998;101(9):1983-91.
6. Li W, Zheng X, Gu JM, Ferrell GL, Brady M, Esmon NL, et al. Extraembryonic expression of EPCR is essential for embryonic viability. Blood 2005;106:2716-22.
7. Sood R, Sholl L, Isermann B, Zogg M, Coughlin SR, Weiler H. Maternal Par4 and platelets contribute to defective placenta formation in mouse embryos lacking thrombomodulin. Blood 2008;112(3):585-91.
8. Sood R, Kalloway S, Mast AE, Hillard CJ, Weiler H. Fetomaternal cross talk in the placental vascular bed: Control of coagulation by trophoblast cells. Blood 2006; 107(8):3173 80.
9. Ganapathy R, Whitley GS, Cartwright JE, Dash PR, Thilaganathan B. Effect of heparin and fractionated heparin on trophoblast invasion. Hum Reprod 2007;22(9): 2523-7.
10. Rodeghiero F, Tosetto A. The epidemiology of inherited thrombophilia: The VITA Project. Vicenza Thrombophilia and Atherosclerosis Project. Thromb Haemost 1997;78(1): 636 40.
11. Wells PS, Anderson JL, Rodger MA, Carson N, Grimwood RL, Doucette SP. The factor XIII Val34Leu polymorphism: Is it protective against idiopathic venous thromboembolism? Blood Coagul Fibrinolysis 2006;17:533-8.
12. Salafia CM, Pezzullo JC, Lopez-Zeno JA, Simmens S, Minior VK, Vintzileos AM. Placental pathologic features of preterm preeclampsia. Am J Obstet Gynecol 1995;173(4): 1097 105.
13. Salafia CM, Ernst LM, Pezzullo JC, Wolf EJ, Rosenkrantz TS, Vintzileos AM. The very low birthweight infant: Maternal complications leading to preterm birth, placental lesions, and intrauterine growth. Am J Perinatol 1995;12(2): 106-10.
14. Rodger MA, Paidas M. Do thrombophilias cause placentamediated pregnancy complications? Semin Thromb Hemost 2007;33:597 603.
15. Infante-Rivard C, Rivard GE, Yotov WV, Genin E, Guiguet M, Weinberg C, et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med 2002;347(1):19 25.
16. Wu O, Robertson L, Twaddle S, Lowe G, Clark P, Walker I, et al. Screening for thrombophilia in high-risk situations: A meta-analysis and cost-effectiveness analysis. Br J Haematol 2005;131:80 90.
17. Howley HE, Walker M, Rodger MA. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol 2005;192:694 708.
18. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: A meta-analysis. Lancet 2003;361(9361): 901-8.
19. Dizon-Townson D, Miller C, Sibai B, Spong CY, Thom E, Wendel Jr G, et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 2005;106(3):517 24.
20. Lindqvist PG, Svensson PJ, Marsaal K, Grennert L, Luterkort M, Dahlback B. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999;81(4): 532-7.
21. Huhle G, Geberth M, Hoffmann U, Heene DL, Harenberg J. Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin. Gynecol Obstet Invest 2000;49(1):67-9.
22. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy. Blood 2005;106:401-7.
23. Bank I, Libourel EJ, Middeldorp S, van der Meer J, Buller HR. High rate of skin complications due to low-molecularweight heparins in pregnant women. J Thromb Haemost 2003;1(4):859-61.
24. Howell R, Fidler J, Letsky E, de Swiet M. The risks of antenatal subcutaneous heparin prophylaxis: A controlled trial. Br J Obstet Gynaecol 1983;90(12):1124-8.
25. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997;314:253-7.
26. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174(5):1584-9.
27. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: A randomized, controlled trial of treatment. Obstet Gynecol 2002;100:408 13.